Medication Error Prevention Analysis
Addison Whitney conducts thorough Medication Error Prevention Analysis (MEPA) research that replicates protocols used by the FDA’s Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation & Research (CBER) and EMA’s Invented Name Review Group (NRG).Based on evolving FDA, EMA and Health Canada guidance, our research reflects the latest policies enforced by the world’s regulatory authorities. Our track record and experience with brand safety research assures your brand will withstand regulatory rigor and get to market.
« BACK TO PHARMACEUTICAL NAME VALIDATION
